Navigation Links
PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Date:8/28/2007

Patrick Gage, Ph.D., executive chairman of PDL's board of directors. "Although we're surprised and disappointed by the Nuvion results in IVSR-UC, we're fortunate to have a portfolio of multiple candidates consistent with our longer-term focus in the targeted areas of oncology and immunology, as well as sufficient resources to advance these opportunities."

Nuvion (visilizumab) Pivotal Program Termination

Following review of data communicated by the Nuvion DMC this past Friday, August 24, PDL has decided that it will no longer pursue its phase 3 program of visilizumab in IVSR-UC, including both the RESTORE 1 and RESTORE 2 studies. The DMC interim evaluation included data from 91 patients in the RESTORE 1 trial at the 45-day primary endpoint. The analysis showed insufficient efficacy and an inferior safety profile in the visilizumab arm compared to IV steroids alone. The company is currently reviewing whether to continue the ongoing dose-ranging trial while it thoroughly evaluates the broader implications of these very recent results to the overall visilizumab program.

New Strategic Direction and Organizational Alignment

PDL has revised its corporate strategy to take advantage of its deep clinical and pre-clinical portfolio, and leverage its ability to innovate in the science and development of monoclonal antibodies. PDL will focus its research and development initiatives and strengthen its expertise in two therapeutic areas -- oncology and select immunological diseases. In oncology, the company's programs include volociximab in a number of solid tumors, HuLuc63 in multiple myeloma, PDL 192 in preclinical development and several additional research stage candidates. PDL's immunological programs include daclizumab in multiple sclerosis and other indications, visilizumab in various potential indications and several preclinical candidates. The company is planning a research and development update in mid-November to detail the status of its R&D init
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 Due ... (FRC) last week, the Adult Stem Cell Technology Center, ... donations to support stem cell therapy research that might benefit ... adult stem cells for new stem cell technologies and therapeutic ... ALS Ice Bucket Challenge donors who wish not ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... Best Sanitizers, Inc., a leader in ... industry, is asking industry professionals to prepare for fall ... E2 soap they’re currently using to the Best Sanitizers’ ... Hand hygiene is critical to fighting cross-contamination and the ... key criteria are identified to evaluate the effectiveness of ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency ... to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager ... plant owners and USDA-GIPSA inspection agencies that have a need ... take place in a matter of minutes with nothing but ... the feed and grain before accepting it, but they no ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... Production of cellulosic ethanol in Scotland, S.D. to start in Q4 ... ... 2008 -- At the American Coalition for Ethanol conference, http://www.poet.com ... million pilot-scale cellulosic ethanol production facility later this year. The pilot ...
... 40.8% to $11.6 million ... Net Income increased 118.8% to $2.5 million, ... Medicine,Corporation (OTC Bulletin Board: CHME) ("China Medicine" or ... and over-the-counter,pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and,dietary-supplements, ...
... DuPont Tate & Lyle Bio Products today announced that its ... as a natural ingredient by ECOCERT®, one of the leading ... ... Loudon, TN August 13, 2008 –- http://www.duponttateandlyle.com/ ...
Cached Biology Technology:POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 2POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 3China Medicine Announces Strong Second Quarter 2008 Results 2China Medicine Announces Strong Second Quarter 2008 Results 3China Medicine Announces Strong Second Quarter 2008 Results 4China Medicine Announces Strong Second Quarter 2008 Results 5China Medicine Announces Strong Second Quarter 2008 Results 6China Medicine Announces Strong Second Quarter 2008 Results 7China Medicine Announces Strong Second Quarter 2008 Results 8China Medicine Announces Strong Second Quarter 2008 Results 9China Medicine Announces Strong Second Quarter 2008 Results 10China Medicine Announces Strong Second Quarter 2008 Results 11Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 2Zemea Propanediol Approved as a Natural Ingredient by ECOCERT 3
(Date:8/28/2014)... traditional cigarettes, but still release toxins into the ... , Scientists studying secondhand smoke from e-cigarettes discovered ... particles, with close-to-zero exposure to organic carcinogens. However, ... second-hand e-cigarette smoke were found to be significantly ... of polycyclic aromatic hydrocarbons cancer-causing organic compounds ...
(Date:8/28/2014)... 2014) Researchers at the University of Minnesota have ... (FSHD) to be used for muscle regeneration research as ... for FSHD. , The research is published in the ... , There is no treatment for FSHD, which is ... of muscular dystrophy. FSHD is an unusual genetic disorder ...
(Date:8/28/2014)... the developmental on-off switch for Streptomyces , a ... of the world,s naturally derived antibiotic medicines. , ... is possible to manipulate this switch to make nature,s ... August 28 in Cell , found that a ... a larger protein called BldD ultimately controls whether a ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... of Sciences will honor 15 individuals with awards in recognition ... fields spanning the physical, biological, and medical sciences. The recipients ... Professor at the Pennsylvania State University, is the recipient of ... being honored for his innovative studies of the flow of ...
... applications as suspensions, engineers need to understand how to ... to understand DST and calculate when it will occur ... from consumer products to cement, a range of industries ... For simple liquids, such as water or ...
... and update of a controversial 20-year-old theory of consciousness ... that consciousness derives from deeper level, finer scale activities ... in "microtubules" inside brain neurons corroborates this theory, according ... They suggest that EEG rhythms (brain waves) also derive ...
Cached Biology News:Academy honors 15 for major contributions to science 2Academy honors 15 for major contributions to science 3Academy honors 15 for major contributions to science 4Academy honors 15 for major contributions to science 5CCNY team models sudden thickening of complex fluids 2Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness 2Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness 3
... Series are a line of pre-integrated ... fast and reliable automated solutions to ... "automation-friendly" building blocks, Caliper has created ... than conventional approaches, take up little ...
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White solid. ... A brain-permeable and water soluble pyrimidinone compound ... + -competitive inhibitor of PARP (IC 50 ... for rhPARP1 and rmPARP2, respectively) with little ...
...
... The Mini-PROTEAN II multiscreen apparatus is used ... 7 cm) gels. The apparatus can screen up ... to cut the blot into strips. The apparatus ... templates that accommodate one or two 8 x ...
Biology Products: